Literature DB >> 26776858

A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer.

Caroline Williamsson1, Johanna Wennerblom2, Bobby Tingstedt1, Claes Jönsson3.   

Abstract

BACKGROUND: A patient with unresectable periampullary malignancy found at laparotomy has traditionally received a prophylactic double bypass (biliary and duodenal), associated with considerable morbidity. With modern endoscopic treatments, surgical bypass has become questionable. This study aims to compare the two strategies. Sahlgrenska University Hospital (SU) performs a double bypass (DoB) routinely, and Skåne University Hospital Lund (SUL) secures biliary drainage endoscopically and treats only symptomatic duodenal obstruction (Wait and See, WaS).
METHOD: Between 2004 and 2013, 73 patients from SU and 70 from SUL were retrospectively identified. Demographics, tumour-related factors and postoperative outcomes during the remaining lifetime were noted.
RESULTS: The DoB group had significantly more complications (67% vs. 31%, p = 0.00002) and longer hospital stay (14 vs. 8 days, p = 0.001) than the WaS-group. The two groups had similar proportion of patients in need of readmission. The DoB patients and the WaS patients with metallic biliary stents were comparable regarding their need of re-interventions and hospitalisation due to biliary obstruction. Surgical duodenal bypass did not prevent future duodenal obstructions.
CONCLUSION: Patients with unresectable periampullary malignancies can safely be managed with endoscopic drainage on demand and with lower morbidity and shorter hospital stay than with surgical prophylactic bypass.
Copyright © 2015 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26776858      PMCID: PMC4750237          DOI: 10.1016/j.hpb.2015.08.009

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  30 in total

1.  Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass.

Authors:  N J Espat; M F Brennan; K C Conlon
Journal:  J Am Coll Surg       Date:  1999-06       Impact factor: 6.113

2.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.

Authors:  K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

Review 3.  Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct.

Authors:  F Michelassi; F Erroi; P J Dawson; A Pietrabissa; S Noda; M Handcock; G E Block
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Surgical palliation for pancreatic cancer. The UCLA experience.

Authors:  S M Singh; W P Longmire; H A Reber
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

5.  Evaluation of palliative surgical procedures in unresectable pancreatic cancer.

Authors:  P D de Rooij; A Rogatko; M F Brennan
Journal:  Br J Surg       Date:  1991-09       Impact factor: 6.939

6.  Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation.

Authors:  Erik Johnsson; Anders Thune; Bengt Liedman
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

7.  Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction.

Authors:  P H Davids; A K Groen; E A Rauws; G N Tytgat; K Huibregtse
Journal:  Lancet       Date:  1992 Dec 19-26       Impact factor: 79.321

Review 8.  Surgical palliation for pancreatic cancer: developments during the past two decades.

Authors:  P Watanapa; R C Williamson
Journal:  Br J Surg       Date:  1992-01       Impact factor: 6.939

9.  Palliative management of malignant antro-pyloric strictures. Gastroenterostomy vs. endoscopic stenting. A randomized prospective trial.

Authors:  Enrico Fiori; Antonietta Lamazza; Patrizia Volpino; Antonio Burza; Claudia Paparelli; Giuseppe Cavallaro; Alberto Schillaci; Vincenzo Cangemi
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  5 in total

1.  [Prophylactic double bypass for unresectable pancreatic cancer : A gain for the patient?]

Authors:  M Schrempf; M Anthuber
Journal:  Chirurg       Date:  2016-12       Impact factor: 0.955

2.  Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches

Authors:  Seung Eun Lee; Sung-Sik Han; Chang Moo Kang; Wooil Kwon; Kwang Yeol Paik; Ki Byung Song; Jae Do Yang; Jun Chul Chung; Chi-Young Jeong; Sun-Whe Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

3.  Double Stenting for Malignant Biliary and Duodenal Obstruction: A Systematic Review and Meta-Analysis.

Authors:  Anna Fábián; Renáta Bor; Noémi Gede; Péter Bacsur; Dániel Pécsi; Péter Hegyi; Barbara Tóth; Zsolt Szakács; Áron Vincze; István Ruzsics; Zoltán Rakonczay; Bálint Erőss; Róbert Sepp; Zoltán Szepes
Journal:  Clin Transl Gastroenterol       Date:  2020-04       Impact factor: 4.396

Review 4.  The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.

Authors:  Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

5.  Surgical exploration without resection in pancreatic and periampullary tumors: Report from a national database.

Authors:  Emil Sahlström; Johan Nilsson; Bobby Tingstedt; Magnus Bergenfeldt; Roland Andersson; Bodil Andersson
Journal:  Scand J Surg       Date:  2020-04-17       Impact factor: 2.360

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.